Health Canada NDS Requirements: What to Include in Your New Drug Submission
A Health Canada NDS is organized in five CTD modules: Module 1 (Canadian administrative documents, including the HC/SC 3011 form and Product Monograph), Module 2 (summaries), Module 3 (CMC/quality data), Module 4 (non-clinical reports), and Module 5 (clinical study reports), as specified under Food and Drug Regulations C.08.002 and C.08.003. Sponsors should confirm the current electronic filing format that applies to their activity before filing.
Key Takeaways
Key Takeaways
- Module 1 is region-specific and includes the HC/SC 3011 form, the Canadian Product Monograph, and other Canada-only administrative documents.
- The Product Monograph should follow Health Canada's current Product Monograph guidance and include Patient Medication Information.
- Right of reference via Letter of Authorization allows cross-referencing Drug Master Files (DMFs) or other sponsors' data without physically including it in the NDS.
- Canada provides 8 years of data protection for innovative drugs under C.08.004.1, with a possible 6-month pediatric extension.
- Health Canada NDS requirements define the complete data package a sponsor must submit to obtain a Notice of Compliance (NOC) and Drug Identification Number (DIN) for a new drug product in Canada. These requirements are codified in Division 8 of the Food and Drug Regulations (C.R.C., c. 870), specifically sections C.08.002 and C.08.003, which establish what information must be provided to demonstrate a drug's safety, efficacy, and quality.
- Understanding the specific content requirements for each CTD module, with particular attention to Canada-specific elements in Module 1, is essential for avoiding screening deficiency notices and review delays.
- In this guide, you will learn:
- Module-by-module content requirements for a Health Canada NDS
- Canadian Product Monograph format and content expectations
- Labeling requirements under the Food and Drug Regulations
- Right of reference and Drug Master File procedures
- ANDS requirements and the Canadian Reference Product concept
- ---
Regulatory Framework: Food and Drug Regulations C.08
The legal basis for NDS content requirements is found in Division 8 of the Food and Drug Regulations. The key sections governing what must be included:
C.08.002(1) states that a manufacturer who seeks a Notice of Compliance for a new drug shall file a new drug submission containing sufficient information and material to assess the safety and effectiveness of the new drug, including:
- Detailed chemistry and manufacturing information (Module 3)
- Results of non-clinical studies (Module 4)
- Results of clinical studies (Module 5)
- The proposed labeling and Product Monograph
- Information on the drug's properties, including its qualitative and quantitative composition
C.08.003 provides additional specificity on the required content, including requirements for samples, stability data, and manufacturing process descriptions.
The Food and Drug Regulations do not prescribe the exact electronic document format. Sponsors should follow Health Canada's live filing guidance, which identifies accepted electronic formats and the applicable technical requirements for each activity type.
Module 1: Administrative Information and Prescribing Information
Module 1 is entirely region-specific. The Health Canada Module 1 structure differs from FDA, EMA, and other regional Module 1 specifications.
1.1 Comprehensive Table of Contents
The eCTD XML backbone generates the table of contents automatically. No separate document is required if the eCTD is properly structured.
1.2 Application Forms and Administrative Documents
HC/SC 3011 (Drug Submission Application Form)
This is the primary application form for all drug submissions to Health Canada. It captures:
- Sponsor name, address, and contact information
- Submission type (NDS, ANDS, SNDS, etc.)
- Drug product details: proper name, proposed brand name, dosage form, route of administration, strength
- Proposed indication(s)
- Manufacturing site information
- Declaration and signature
The form should be completed using the current Health Canada version and included in the filing package.
Fee payment documentation
Health Canada publishes current fee and payment instructions separately. Sponsors should include the payment information or confirmation required by the current filing instructions.
1.3 Product Monograph
The Product Monograph (PM) is the Canadian prescribing information document. It is the single most important Module 1 document and is unique to the Canadian regulatory system.
Format requirements:
Health Canada's Product Monograph guidance describes a structured template that includes:
| Part | Content |
|---|---|
| Part I: Health Professional Information | Indications, contraindications, warnings, precautions, adverse reactions, drug interactions, dosage, pharmacology, clinical trials summary |
| Part II: Scientific Information | Pharmaceutical information, clinical trials, detailed pharmacology, toxicology, references |
| Patient Medication Information | Patient-facing summary of the drug information |
Key formatting rules:
- The PM should follow Health Canada's current Product Monograph guidance and template
- Brand name, proper name (INN), and dosage form must appear on the title page
- Tables and figures must be embedded within the text, not appended separately
- The document must be submitted as a PDF that meets eCTD specifications (fonts embedded, bookmarks for each section)
Bilingual requirements:
Sponsors should verify the current bilingual filing and marketed-labeling expectations in the applicable Health Canada Product Monograph and labeling guidance.
Patient Medication Information (PMI):
The Product Monograph includes Patient Medication Information written in plain language. The PMI is intended for distribution to patients and includes:
- What the drug is and what it is used for
- How to take the drug
- Side effects and what to do about them
- Storage conditions
- Full prescribing information reference
1.4 Labeling
Labeling for the inner and outer containers must comply with C.01.004 of the Food and Drug Regulations. Required label elements include:
| Element | Requirement |
|---|---|
| Brand name | Must not be misleading; subject to Health Canada review |
| Proper name (INN) | Required on all labels |
| DIN | Added after NOC issuance, before marketing |
| Quantitative statement | Strength per dosage unit |
| Dosage form | As described in submission |
| Route of administration | As approved |
| Net contents | Quantity of drug in container |
| Manufacturer or sponsor information | As required by the applicable labeling rules |
| Lot number | Required on all commercial labels |
| Expiry date | Required on all commercial labels |
| Storage conditions | As established by stability data |
| Bilingual text | English and French required for marketed products |
Mock-up labels (drafts showing proposed label content and layout) must be included in the NDS. Final labels with the DIN are finalized after NOC issuance.
1.5 Right of Reference and Drug Master Files
Right of Reference (RoR)
A right of reference allows the sponsor to cross-reference data held in another sponsor's submission or in a Drug Master File (DMF) without physically including that data in the NDS. This is commonly used for:
- Active pharmaceutical ingredient (API) data held in a DMF filed by the API manufacturer
- Reference to data in a previously approved submission (e.g., a previously approved product by the same sponsor)
To exercise a right of reference, the sponsor must include in Module 1.5:
- A Letter of Authorization from the data owner granting the right of reference
- The DMF number or submission control number being referenced
- A clear identification of which data is being cross-referenced
Drug Master Files (DMFs)
Health Canada accepts Drug Master Files filed by API manufacturers, excipient suppliers, or other parties who wish to provide confidential data to support a drug submission without disclosing it to the drug sponsor.
DMFs are filed directly with Health Canada and assigned a DMF number. The DMF holder provides a Letter of Authorization to the drug sponsor, who references the DMF number in their NDS.
DMF content typically covers:
- API manufacturing process and controls
- Specifications and analytical methods
- Stability data
- Impurity profiles
Module 2: Common Technical Document Summaries
Module 2 follows the standard ICH CTD format and contains summaries of the quality, non-clinical, and clinical information.
Required Module 2 Components
| Section | Document | Description |
|---|---|---|
| 2.2 | Introduction | Brief overview of the drug and its development |
| 2.3 | Quality Overall Summary (QOS) | Summary of Module 3 CMC data |
| 2.4 | Non-clinical Overview | Integrated assessment of non-clinical data |
| 2.5 | Clinical Overview | Integrated clinical assessment of benefit-risk |
| 2.6 | Non-clinical Written and Tabulated Summaries | Detailed summaries with tables |
| 2.7 | Clinical Summary | Detailed clinical summaries: biopharmaceutics, clinical pharmacology, efficacy, safety |
Health Canada uses the standard ICH CTD structure for Module 2, with Canada-specific administrative material handled in Module 1.
Module 3: Quality (Chemistry, Manufacturing, and Controls)
Module 3 contains the complete quality dossier and follows the ICH M4Q structure. Health Canada's expectations align with ICH guidelines, with some Canadian-specific considerations.
Module 3 Structure
| Section | Content |
|---|---|
| 3.2.S | Drug Substance (API) |
| 3.2.S.1 | General information (nomenclature, structure, properties) |
| 3.2.S.2 | Manufacture (manufacturer, process, controls, process validation) |
| 3.2.S.3 | Characterization (elucidation of structure, impurities) |
| 3.2.S.4 | Control of drug substance (specifications, analytical procedures, validation, batch analyses, justification) |
| 3.2.S.5 | Reference standards |
| 3.2.S.6 | Container closure system |
| 3.2.S.7 | Stability (protocol, data, conclusions) |
| 3.2.P | Drug Product |
| 3.2.P.1 | Description and composition |
| 3.2.P.2 | Pharmaceutical development |
| 3.2.P.3 | Manufacture (batch formula, process, controls, validation) |
| 3.2.P.4 | Control of excipients |
| 3.2.P.5 | Control of drug product (specifications, methods, validation, batch analyses) |
| 3.2.P.6 | Reference standards |
| 3.2.P.7 | Container closure system |
| 3.2.P.8 | Stability |
| 3.2.A | Appendices (facilities, adventitious agents, novel excipients) |
| 3.2.R | Regional information |
| 3.3 | Literature references |
Canadian-Specific Module 3 Considerations
Drug Establishment Licence (DEL): Under C.01A.003 of the Food and Drug Regulations, an establishment in Canada that fabricates, packages, labels, tests, imports, distributes, or wholesales drugs must hold a DEL.
Comparative standards: If the product references a Canadian Reference Product, comparative dissolution or bioequivalence data should be included in Module 3 or Module 5 as appropriate.
Module 4: Non-clinical Study Reports
Module 4 follows the standard ICH M4S format and contains all non-clinical pharmacology and toxicology study reports.
Required Module 4 Content
| Section | Content |
|---|---|
| 4.2.1 | Pharmacology (primary, secondary, safety) |
| 4.2.2 | Pharmacokinetics (absorption, distribution, metabolism, excretion) |
| 4.2.3 | Toxicology (single dose, repeat dose, genotoxicity, carcinogenicity, reproductive toxicology, local tolerance, other) |
Health Canada expects non-clinical studies to comply with Good Laboratory Practice (GLP) as defined by the OECD Principles of Good Laboratory Practice. Study reports should include GLP compliance statements.
For biologics submitted to BRDD, additional non-clinical requirements may apply, including immunogenicity assessments and species selection justification.
Module 5: Clinical Study Reports
Module 5 contains the clinical data package supporting the safety and efficacy claims in the NDS. The structure follows ICH E3 (Structure and Content of Clinical Study Reports) and ICH M4E.
Required Module 5 Content
| Section | Content |
|---|---|
| 5.2 | Tabular listing of all clinical studies |
| 5.3.1 | Biopharmaceutic study reports (bioavailability, bioequivalence, in vitro dissolution) |
| 5.3.2 | Studies pertinent to pharmacokinetics using human biomaterials |
| 5.3.3 | Reports of human pharmacokinetic studies |
| 5.3.4 | Reports of human pharmacodynamic studies |
| 5.3.5 | Reports of efficacy and safety studies |
| 5.3.6 | Reports of post-marketing experience |
| 5.3.7 | Case report forms and individual patient listings |
Canadian-Specific Clinical Considerations
Sponsors should verify any product-specific pediatric, pharmacovigilance, and population-bridging expectations against the current Health Canada guidance relevant to the product class and indication.
ANDS: Abbreviated New Drug Submission Requirements
An Abbreviated New Drug Submission (ANDS) is the Canadian pathway for generic drug products, analogous to the FDA's ANDA (Abbreviated New Drug Application). The ANDS requirements are defined under C.08.002.1 of the Food and Drug Regulations.
ANDS Content Requirements
An ANDS includes:
| Component | Description |
|---|---|
| Module 1 | Same administrative requirements as NDS (forms, PM, labeling, fees) |
| Module 2 | Quality Overall Summary, abbreviated clinical/non-clinical summaries |
| Module 3 | Full CMC data for the generic product |
| Module 4 | Generally not required (may reference CRP non-clinical data) |
| Module 5 | Bioequivalence study report(s) demonstrating equivalence to CRP |
Canadian Reference Product (CRP)
The Canadian Reference Product is a drug product that has received a Notice of Compliance in Canada and is listed in Health Canada's Drug Product Database. The ANDS sponsor must demonstrate that their generic product is bioequivalent to the CRP.
A CRP is a drug product that has received a Notice of Compliance in Canada and is identified in accordance with Health Canada's generic-drug policies. Sponsors should verify current CRP acceptability, including any foreign-reference options, against the applicable Health Canada guidance before filing.
Bioequivalence Requirements
Bioequivalence studies for an ANDS must comply with Health Canada's "Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies" and related guidance. Key requirements:
- Studies must be conducted in healthy volunteers (unless otherwise justified)
- A randomized, crossover design is standard
- Both fasting and fed studies are typically required for oral solid dosage forms
- Acceptance criteria: 90% confidence interval for AUC and Cmax within 80.00-125.00%
- Study design and statistical analysis should follow the current Health Canada comparative bioavailability guidance and any superseding ICH implementation notices
Data Protection and Market Exclusivity
Canada provides data protection for innovative drugs through C.08.004.1 of the Food and Drug Regulations. Understanding these provisions is relevant for both NDS and ANDS filers.
Innovative Drug Data Protection
- 8 years of data protection: The data protection provisions provide an eight-year period of market exclusivity for an innovative drug.
- 6-month pediatric extension: An additional 6 months of data protection may be granted if the innovator conducts pediatric studies requested by Health Canada, extending the total protection to 8.5 years.
Note: Canadian data protection terms differ from the US (where Hatch-Waxman provides 5 years for NCEs plus potential patent term extensions) and from the EU (where 8+2+1 years of data exclusivity, market protection, and potential pediatric extension apply).
Common NDS Deficiencies and How to Avoid Them
The following issues commonly create screening or review problems if they are not addressed clearly:
Module 1 Deficiencies
| Issue | Why it matters |
|---|---|
| Incorrect or incomplete HC/SC 3011 | Can delay administrative processing |
| Product Monograph uses an outdated structure | Can create screening or review questions |
| Missing Patient Medication Information | Leaves the Product Monograph incomplete |
| Missing payment information | Can delay filing progress |
Module 3 Deficiencies
| Issue | Why it matters |
|---|---|
| Stability package does not support the proposed shelf life or retest period | Can create review questions |
| Specifications are not well justified | Can prompt clarification requests |
| Batch analysis or validation support is incomplete | Can weaken the CMC package |
Module 5 Deficiencies
| Issue | Why it matters |
|---|---|
| Incomplete clinical reports or summaries | Can delay review |
| Unclear study relevance or context | Can prompt requests for clarification |
| Missing supporting pharmacovigilance material where requested | Can leave the package incomplete |
The Canadian Product Monograph is a three-part document (Health Professional Information, Scientific Information, and Patient Medication Information) that combines prescribing information and patient-facing content in a single document. The US Prescribing Information (USPI), governed by FDA labeling requirements, is a separate document from the Patient Package Insert. The PM follows a Health Canada-specific template and includes more detailed pharmacology and toxicology summaries than the USPI.
Key Regulatory References
- Food and Drug Regulations
- Guidance on management of drug submissions and applications: pre-application and filing
- Guidance Document: Product Monograph
- Guidance on procedures and administrative requirements for master files
- Guidance Document: Data Protection under C.08.004.1 of the Food and Drug Regulations
- Notice to stakeholders – Implementation of ICH M13A: Bioequivalence for immediate release solid oral dosage forms
- ICH M4 Organisation of the Common Technical Document for the Registration of Pharmaceuticals for Human Use
- ICH E3 Structure and Content of Clinical Study Reports
- ICH E5 Ethnic Factors in the Acceptability of Foreign Clinical Data
References
This guide reflects Health Canada NDS requirements as of early 2026. Sponsors should verify current requirements against Health Canada's official guidance documents, as regulatory expectations and templates are periodically updated.